← Back to Search

Unknown

ADX-629 for Nephrotic Syndrome

Phase 2

Waitlist Available

Research Sponsored by Aldeyra Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from day 1 to day 90

Awards & highlights

Study Summary

This trial tests a new medicine to help people with kidney disease who need to take steroids often.

Eligible Conditions

Nephrotic Syndrome

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from day 1 to day 90

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from day 1 to day 90

This trial's timeline: 3 weeks for screening, Varies for treatment, and from day 1 to day 90 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adverse Event (AE) Query

Secondary outcome measures

Relapse Frequency

Trial Design

1Treatment groups

Experimental Treatment

Group I: ADX-629Experimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

ADX-629

2021

Completed Phase 2

~110

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Aldeyra Therapeutics, Inc.Lead Sponsor

29 Previous Clinical Trials

4,028 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What risk factors have been associated with the use of ADX-629?

"Our team concluded that ADX-629 carried a safety rating of 2. This reflects the fact that Phase 2 clinical trials provide some evidence for its security, though there is no data yet pertaining to efficacy."

Answered by AI

Are the recruitment criteria for this trial currently open?

"According to the information posted on clinicaltrials.gov, this particular medical study is no longer recruiting patients. First published on November 1st 2022, and last updated a month later in October, it has now been superseded by 1395 other active trials looking for participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

2023. "Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05599815.

All > Nephrotic Syndrome